Novo Nordisk Receives Marketing Authorisation For Victoza

Published: 03-Jul-2009

Victoza, once-daily human Glucagon-Like Peptide-1 analogue, developed for the treatment of type 2 diabetes

European Commission has granted marketing authorisation for Novo Nordisk' Victoza, for the treatment of type 2 diabetes in adults. The authorisation covers all 27 EU member states.

Victoza is the brand name approved in Europe for liraglutide, the once-daily human Glucagon-Like Peptide-1 (GLP-1) analogue developed for the treatment of type 2 diabetes.

Mads Thomsen, Executive Vice President and Chief Science Officer of Novo Nordisk, said: This is an important milestone for Novo Nordisk and for the treatment of type 2 diabetes. In clinical studies involving more than 6,500 people with type 2 diabetes, Victoza has been shown to have a significant blood glucose-lowering effect and lead to weight loss, while having a low risk of hypoglycaemia. On this background, we are convinced that Victoza is a valuable new treatment option for people with type 2 diabetes.

Novo Nordisk would launch Victoza in the UK, Germany and Denmark during the summer, and in other European markets during the second half of 2009 and throughout 2010.

Tell your friend about this article